左西孟旦治疗心衰的临床研究进展  

Progress in clinical research on levosimendan in treatment of heart failure

作　　者：余星燕[1] 邢坤[2] 

机构地区：[1]延安大学医学院,陕西延安716000 [2]陕西省人民医院老年心血管内科,陕西西安710068

出　　处：《心脏杂志》2013年第6期739-741,745,共4页Chinese Heart Journal

摘　　要：左西孟旦(levosimendan,LS)是一种新型钙增敏剂,其正性肌力作用主要通过增加心肌肌钙蛋白对Ca2+的敏感性和开放细胞膜上ATP敏感的K+通道,增加心肌收缩力,同时扩张外周血管和冠状动脉,减轻心脏前后负荷。LS目前主要用于治疗急性和顽固性心力衰竭(HF)。国内外指南已将其列为IIa类(B级证据),为HF的药物治疗增加了选择。Levosimendan, a new calcium sensitizer agent, increases myocardial contractility and peripheral and coronary blood vessel vasodilation and reduces preload and afterload via increasing calcium sensitization of cardiac troponin and opening ATPsensitive potassium channels on cell membranes. Levosimendan is currently used mainly in the treatment of decompensated heart failure （HF）. The guidelines both at home and abroad have classified it as Class IIa （level of evidence B） for treatment of acute HF in drug selection.

关 键 词：左西孟旦 正性肌力药物 钙离子增敏剂 心力衰竭 

分 类 号：R541.6[医药卫生—心血管疾病]